文献速递其他结缔组织病

尼达尼布对系统性硬化相关间质性肺病肺功能的影响:随机双盲安慰剂对照试验的进一步分析

Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial.
PubMed 文献 · Arthritis Rheumatol · 2021-03-08

基于SENSCIS试验的事后分析,288例接受尼达尼布、288例接受安慰剂。第52周时尼达尼布组FVC占预计值下降≥10%或死亡的风险显著低于安慰剂组(HR 0.64,95%CI 0.43-0.95,P=0.029),提示尼达尼布对SSc-ILD进展有临床相关获益。

要点

  • 尼达尼布组FVC占预计值绝对下降≥10%或死亡风险较安慰剂组显著降低(HR 0.64)。
  • FVC占预计值绝对下降≥5%或死亡风险两组差异无统计学意义(HR 0.83,P=0.14)。
  • 第52周尼达尼布组FVC占预计值改善≥3.0%的比例高于安慰剂组(23.0% vs 14.9%)。

核心结论

  • 尼达尼布对SSc-ILD进展具有临床相关获益,尤其体现在降低FVC占预计值绝对下降≥10%或死亡的风险。

研究设计与样本

  • SENSCIS试验的事后分析,288例接受尼达尼布、288例接受安慰剂,评估第52周FVC分类变化及FVC绝对下降或死亡的时间。

主要发现

  • 第52周尼达尼布组与安慰剂组分别有55.7%和66.3%出现FVC占预计值任何下降。
  • 尼达尼布组与安慰剂组分别有13.6%和20.1%出现FVC占预计值下降>5%至≤10%。
  • 尼达尼布组与安慰剂组分别有3.5%和5.2%出现FVC占预计值下降>10%至≤15%。
  • 尼达尼布组与安慰剂组分别有34.5%和43.8%出现FVC占预计值下降≥3.3%(拟议的FVC恶化MCID)。
  • 尼达尼布组与安慰剂组分别有23.0%和14.9%出现FVC占预计值改善≥3.0%(拟议的FVC改善MCID)。

关键数值与推荐

  • 52周内FVC占预计值绝对下降≥5%或死亡的风险比尼达尼布组对安慰剂组为0.83(95%CI 0.66-1.06,P=0.14)。
  • 52周内FVC占预计值绝对下降≥10%或死亡的风险比尼达尼布组对安慰剂组为0.64(95%CI 0.43-0.95,P=0.029)。

临床怎么用

  • 对于SSc-ILD患者,尼达尼布可考虑用于减缓FVC占预计值绝对下降≥10%或死亡的风险。

局限性

  • 本研究为事后分析,FVC分类变化及MCID相关结果为探索性,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In the SENSCIS trial in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks by 44% versus placebo. This study was undertaken to investigate the effects of nintedanib on categorical changes in FVC and other measures of ILD progression. METHODS: In post hoc analyses, we assessed the proportions of subjects with categorical changes in FVC % predicted at week 52 and the time to absolute decline in FVC of ≥5% predicted or death and absolute decline in FVC of ≥10% predicted or death. RESULTS: A total of 288 subjects received nintedanib and 288 subjects received placebo. At week 52, in subjects treated with nintedanib and placebo, respectively, 55.7% and 66.3% had any decline in FVC % predicted, 13.6% and 20.1% had a decline in FVC of >5% to ≤10% predicted, and 3.5% and 5.2% had a decline in FVC of >10% to ≤15% predicted; 34.5% and 43.8% had a decrease in FVC of ≥3.3% predicted (proposed minimal clinically important difference [MCID] for worsening of FVC), while 23.0% and 14.9% had an increase in FVC of ≥3.0% predicted (proposed MCID for improvement in FVC). Over 52 weeks, the hazard ratio (HR) for an absolute decline in FVC of ≥5% predicted or death with nintedanib versus placebo was 0.83 (95% confidence interval [95% CI] 0.66-1.06) (P = 0.14), and the HR for an absolute decline in FVC of ≥10% predicted was 0.64 (95% CI 0.43-0.95) (P = 0.029). CONCLUSION: These results suggest that nintedanib has a clinically relevant benefit on the progression of SSc-ILD.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Maher TM, Mayes MD, Kreuter M, et al. Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2021. PMID: 33142016. doi:10.1002/art.41576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。